The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma - PubMed (original) (raw)
P Arlen, J Gulley, A Rogatko, H S Cooper, N J Meropol, R K Alpaugh, M Davey, S McLaughlin, M T Beard, K Y Tsang, J Schlom, L M Weiner
Affiliations
- PMID: 11350882
Clinical Trial
The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma
M von Mehren et al. Clin Cancer Res. 2001 May.
Abstract
Granulocyte macrophage colony-stimulating factor (GM-CSF) has been shown to be an effective vaccine adjuvant because it enhances antigen processing and presentation by dendritic cells. ALVAC-CEA B7.1 is a canarypox virus encoding the gene for the tumor-associated antigen carcinoembryonic antigen (CEA) and for a T-cell costimulatory molecule, B7.1. After an initial dose escalation phase, this study evaluated vaccination with 4.5 x 10(8) plaque-forming units ALVAC-CEA B7.1 alone (n = 30) or with GM-CSF (n = 30) in patients with advanced CEA-expressing tumors to determine whether the addition of the adjuvant GM-CSF enhances induction of CEA-specific T-cells. Patients were vaccinated with vaccine intradermally every other week for 8 weeks. GM-CSF was given s.c. for 5 days beginning 2 days before vaccination. Patients with stable or responding disease after four immunizations received monthly boost injections alone or with GM-CSF. Biopsies of vaccine sites were obtained 48 h after vaccination to evaluate leukocytic infiltration and CEA expression. Induction of peripheral blood CEA-specific T-cell precursors was assessed in HLA-A2 positive patients by an ELISPOT assay looking for the production of IFN-gamma. Therapy was well tolerated. All of the patients had evidence of leukocytic infiltration and CEA expression in vaccine biopsy sites. In the patients receiving GM-CSF, leukocytic infiltrates were greater in cell number but were less likely to have a predominant lymphocytic infiltrate compared with patients receiving vaccine in the absence of the cytokine adjuvant. After four vaccinations, CEA-specific T-cell precursors were statistically increased in HLA-A2 positive patients who received vaccine alone. However, the GM-CSF plus vaccine cohort of HLA-A2 positive did not demonstrate a statistically significant increase in their CEA-specific T-cell precursor frequencies compared with baseline results. The number of prior chemotherapy regimens was negatively correlated with the generation of a T-cell response, whereas there was a positive correlation between the number of months from the last chemotherapy regimen and the T-cell response. ALVAC-CEA B7.1 is safe in patients with advanced, recurrent adenocarcinomas that express CEA, is associated with the induction of a CEA-specific T-cell response in patients treated with vaccine alone but not with vaccine and GM-CSF, and can lead to disease stabilization for up to 13 months.
Similar articles
- Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas.
von Mehren M, Arlen P, Tsang KY, Rogatko A, Meropol N, Cooper HS, Davey M, McLaughlin S, Schlom J, Weiner LM. von Mehren M, et al. Clin Cancer Res. 2000 Jun;6(6):2219-28. Clin Cancer Res. 2000. PMID: 10873071 Clinical Trial. - Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
Marshall JL, Gulley JL, Arlen PM, Beetham PK, Tsang KY, Slack R, Hodge JW, Doren S, Grosenbach DW, Hwang J, Fox E, Odogwu L, Park S, Panicali D, Schlom J. Marshall JL, et al. J Clin Oncol. 2005 Feb 1;23(4):720-31. doi: 10.1200/JCO.2005.10.206. Epub 2004 Dec 21. J Clin Oncol. 2005. PMID: 15613691 Clinical Trial. - Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J. Hodge JW, et al. Clin Cancer Res. 2003 May;9(5):1837-49. Clin Cancer Res. 2003. PMID: 12738742 - Future uses of granulocyte-macrophage colony-stimulating factor (GM-CSF).
Jones TC. Jones TC. Stem Cells. 1994;12 Suppl 1:229-39; discussion 239-40. doi: 10.1002/stem.5530120719. Stem Cells. 1994. PMID: 7696962 Review. - GM-CSF-secreting vaccines for solid tumors.
Emens LA. Emens LA. Curr Opin Investig Drugs. 2009 Dec;10(12):1315-24. Curr Opin Investig Drugs. 2009. PMID: 19943203 Review.
Cited by
- Efficacy and safety of BVAC-C in HPV type 16- or 18-positive cervical carcinoma who failed 1st platinum-based chemotherapy: a phase I/IIa study.
Choi CH, Lee JW, Bae DS, Kang ES, Cho D, Kim YM, Kim K, Kim JW, Kim HS, Kim YT, Lee JY, Lim MC, Oh T, Song B, Jeon I, Park M, Kim WH, Kang CY, Kim BG. Choi CH, et al. Front Immunol. 2024 Mar 28;15:1371353. doi: 10.3389/fimmu.2024.1371353. eCollection 2024. Front Immunol. 2024. PMID: 38605958 Free PMC article. Clinical Trial. - Colorectal cancer vaccines: The current scenario and future prospects.
Jia W, Zhang T, Huang H, Feng H, Wang S, Guo Z, Luo Z, Ji X, Cheng X, Zhao R. Jia W, et al. Front Immunol. 2022 Aug 3;13:942235. doi: 10.3389/fimmu.2022.942235. eCollection 2022. Front Immunol. 2022. PMID: 35990683 Free PMC article. Review. - Cancer Vaccines: Promising Therapeutics or an Unattainable Dream.
Donninger H, Li C, Eaton JW, Yaddanapudi K. Donninger H, et al. Vaccines (Basel). 2021 Jun 18;9(6):668. doi: 10.3390/vaccines9060668. Vaccines (Basel). 2021. PMID: 34207062 Free PMC article. Review. - The Journey of in vivo Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road.
Goyvaerts C, Breckpot K. Goyvaerts C, et al. Front Immunol. 2018 Sep 11;9:2052. doi: 10.3389/fimmu.2018.02052. eCollection 2018. Front Immunol. 2018. PMID: 30254636 Free PMC article. Review. - The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy.
Roselli M, Formica V, Cereda V, Jochems C, Richards J, Grenga I, Orlandi A, Ferroni P, Guadagni F, Schlom J. Roselli M, et al. Oncoimmunology. 2016 May 19;5(7):e1188243. doi: 10.1080/2162402X.2016.1188243. eCollection 2016 Jul. Oncoimmunology. 2016. PMID: 27622042 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials